Document Detail


Starch-poly-epsilon-caprolactone microparticles reduce the needed amount of BMP-2.
MedLine Citation:
PMID:  19557487     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BMP-2 is currently administered clinically using collagen matrices often requiring large amounts of BMP-2 due to burst release over a short period of time. We developed and tested a novel injectable drug delivery system consisting of starch-poly-epsilon-caprolactone microparticles for inducing osteogenesis and requiring smaller amounts of BMP-2. We evaluated BMP-2 encapsulation efficiency and the in vitro release profile by enzyme-linked immunosorbent assay. BMP-2 was rapidly released during the first 12 hours, followed by sustained release for up to 10 days. We then evaluated the osteogenic potential of dexamethasone (standard osteogenic induction agent) and BMP-2 after incorporation and during release using an osteo/myoblast cell line (C2C12). Alkaline phosphatase activity was increased by released BMP-2. Mineralization occurred after stimulation with BMP-2-loaded microparticles. A luciferase assay for osteocalcin promoter activity showed high levels of activity upon treatment with BMP-2-loaded microparticles. In contrast, no osteogenesis occurred in C2C12 cells using dexamethasone-loaded microparticles. However, human adipose stem cells exposed to the microparticles produced high amounts of alkaline phosphatase. The data suggest starch-poly-epsilon-caprolactone microparticles are suitable carriers for the incorporation and controlled release of glucocorticoids and growth factors. Specifically, they reduce the amount of BMP-2 needed and allow more sustained osteogenic effects.
Authors:
E R Balmayor; G A Feichtinger; H S Azevedo; M van Griensven; R L Reis
Related Documents :
2524577 - T cells and t-cell subsets in periodontal diseases.
17092287 - Co-alkene polymers are biocompatible scaffolds for primary urothelial cells in vitro an...
15878367 - A synthetic nanofibrillar matrix promotes in vivo-like organization and morphogenesis f...
7787797 - Myelopoietic competence of stroma composed of hepatic granuloma-derived connective tiss...
12898847 - Neuroprotective effect of acth (4-9) in degeneration of hippocampal nerve cells caused ...
2328737 - Involvement of mitochondria in cell degeneration.
Publication Detail:
Type:  Journal Article     Date:  2009-06-26
Journal Detail:
Title:  Clinical orthopaedics and related research     Volume:  467     ISSN:  1528-1132     ISO Abbreviation:  Clin. Orthop. Relat. Res.     Publication Date:  2009 Dec 
Date Detail:
Created Date:  2009-11-05     Completed Date:  2010-01-05     Revised Date:  2013-06-02    
Medline Journal Info:
Nlm Unique ID:  0075674     Medline TA:  Clin Orthop Relat Res     Country:  United States    
Other Details:
Languages:  eng     Pagination:  3138-48     Citation Subset:  AIM; IM    
Affiliation:
3B's Research Group-Biomaterials, Biodegradables and Biomimetics, Department of Polymer Engineering, University of Minho, Headquarters of European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark, Zona Industrial da Gandra, Caldas das Taipas, Guimarães, Portugal. erosado@dep.uminho.pt.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adipose Tissue / cytology,  drug effects,  metabolism
Alkaline Phosphatase / metabolism
Animals
Bone Morphogenetic Protein 2 / administration & dosage,  chemistry,  pharmacology*
Calcification, Physiologic / drug effects
Cell Differentiation / drug effects*
Cell Line
Delayed-Action Preparations
Dexamethasone / administration & dosage,  chemistry,  pharmacology*
Dose-Response Relationship, Drug
Drug Carriers*
Drug Compounding
Humans
Injections
Kinetics
Mice
Osteoblasts / drug effects*,  metabolism
Osteocalcin / genetics
Osteogenesis / drug effects*
Particle Size
Polyesters / chemistry*
Promoter Regions, Genetic / drug effects
Solubility
Starch / chemistry*
Stem Cells / drug effects,  metabolism
Chemical
Reg. No./Substance:
0/Bone Morphogenetic Protein 2; 0/Delayed-Action Preparations; 0/Drug Carriers; 0/Polyesters; 0/starch polycaprolactone; 104982-03-8/Osteocalcin; 50-02-2/Dexamethasone; 9005-25-8/Starch; EC 3.1.3.1/Alkaline Phosphatase
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Fenestrated cannulae with outflow reduces fluid gain in shoulder arthroscopy.
Next Document:  Fine wigns.